Zeyan Peng1, Shuyang Dong1, Yong Tao2, Yingchao Huo2, Zhenhua Zhou3, Wen Huang4, Hongdang Qu5, Juan Liu2, Yang Chen2, Zhiqiang Xu2, Yanjiang Wang2, Huadong Zhou6. 1. Department of Neurology, Daping Hospital, Third Military Medical University, Chongqing 400042, China; Postgraduate School, Bengbu Medical College, Bengbu, Anhui 233030, China. 2. Department of Neurology, Daping Hospital, Third Military Medical University, Chongqing 400042, China. 3. Department of Neurology, Southwest Hospital, Third Military Medical University, Chongqing 400038, China. 4. Department of Neurology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China. 5. Department of Neurology, The First Affiliated Hospital of Bengbu Medical College, Anhui 233004, China. 6. Department of Neurology, Daping Hospital, Third Military Medical University, Chongqing 400042, China. Electronic address: zhouhuad@163.com.
Abstract
INTRODUCTION: Metabolic syndrome (MetS) increases the risk of cognitive impairment in normal aging but this has not been studied in Parkinson's Disease (PD). The purpose of this study was to investigate the impact of MetS on cognitive impairment in PD. METHODS: This study investigated subjects older than 60 years who were diagnosed with PD. They were enrolled into this study between January 2010 and December 2011, and followed for 5 years. The assessment of cognitive function in subjects with PD was based on the cognitive and neuropsychiatric tests, and MetS was diagnosed according to the National Cholesterol Education Program's Adult Treatment Panel III. The subjects were divided into three groups according to the cognitive function at the end of follow-up: PD with normal cognitive function (PD-NC), mild cognitive impairment in PD (PD-MCI) and PD dementia (PDD). RESULTS: Of the 787 subjects with PD included in our study, 255 (32.4%) were diagnosed with PD-MCI, and 105 (13.3%) were diagnosed with PDD. MetS was significantly associated with PD-MCI (odds radio [OR]: 1.45, 95% confidence interval [CI]: 1.17-1.72) and PDD (OR: 2.12, 95% CI: 1.57-2.83). The associations between MetS and the main cognition domains of PDD were statistically significant. The treatment of MetS was helpful in reducing the risk of PDD. CONCLUSIONS: We found that MetS increase the risk of cognitive impairment in patients with PD, and is significantly associated with the severity of cognitive impairment. The results suggest that the intervention against MetS is helpful in managing cognitive impairment in PD.
INTRODUCTION:Metabolic syndrome (MetS) increases the risk of cognitive impairment in normal aging but this has not been studied in Parkinson's Disease (PD). The purpose of this study was to investigate the impact of MetS on cognitive impairment in PD. METHODS: This study investigated subjects older than 60 years who were diagnosed with PD. They were enrolled into this study between January 2010 and December 2011, and followed for 5 years. The assessment of cognitive function in subjects with PD was based on the cognitive and neuropsychiatric tests, and MetS was diagnosed according to the National Cholesterol Education Program's Adult Treatment Panel III. The subjects were divided into three groups according to the cognitive function at the end of follow-up: PD with normal cognitive function (PD-NC), mild cognitive impairment in PD (PD-MCI) and PD dementia (PDD). RESULTS: Of the 787 subjects with PD included in our study, 255 (32.4%) were diagnosed with PD-MCI, and 105 (13.3%) were diagnosed with PDD. MetS was significantly associated with PD-MCI (odds radio [OR]: 1.45, 95% confidence interval [CI]: 1.17-1.72) and PDD (OR: 2.12, 95% CI: 1.57-2.83). The associations between MetS and the main cognition domains of PDD were statistically significant. The treatment of MetS was helpful in reducing the risk of PDD. CONCLUSIONS: We found that MetS increase the risk of cognitive impairment in patients with PD, and is significantly associated with the severity of cognitive impairment. The results suggest that the intervention against MetS is helpful in managing cognitive impairment in PD.
Authors: Ana Patrícia da Silva Souza; Waleska Maria Almeida Barros; José Maurício Lucas Silva; Mariluce Rodrigues Marques Silva; Ana Beatriz Januário Silva; Matheus Santos de Sousa Fernandes; Maria Eduarda Rodrigues Alves Dos Santos; Mayara Luclécia da Silva; Taciane Silva do Carmo; Roberta Karlize Pereira Silva; Karollainy Gomes da Silva; Sandra Lopes de Souza; Viviane de Oliveira Nogueira Souza Journal: Clinics (Sao Paulo) Date: 2021-12-13 Impact factor: 2.365
Authors: Sabine Schootemeijer; Nicolien M van der Kolk; Bastiaan R Bloem; Nienke M de Vries Journal: Neurotherapeutics Date: 2020-10 Impact factor: 7.620